Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

April 30, 2009

Conditions
Leukemia, Myeloid
Interventions
DRUG

AS1411

AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.

Trial Locations (10)

27710

Duke University Medical Center, Durham

29425

Medical University of South Carolina, Charleston

40202

University of Louisville, James Graham Brown Cancer Center, Louisville

46107

St. Francis Hospital and Health Center, Beech Grove

63110

Washington University, St Louis

68198

University of Nebraska Medical Center, Omaha

78229

Cancer Therapy and Research Center - Institute for Drug development, San Antonio

80010

Univeristy of Colorado Health Cancer Center, Aurora

90095

UCLA Medical Center, Los Angeles

Unknown

Christchurch Hospital, Christchurch

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Antisoma Research

INDUSTRY